Australia's Sirtex expects approval for Chinese buyout
June 15, 2018 at 01:23 AM EDT
SYDNEY, June 15 (Reuters) - Australian liver cancer treatment maker Sirtex Medical Ltd expects its $1.4 billion buyout by a Chinese consortium to will win regulatory approval in Australia and the United States despite diplomatic tensions with China.